Bionano Genomics Announces Publication of Study in MDS and AML Showing Utility for Refined Diagnostics and Prognostic Stratification
September 14 2022 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the
publication of a study evaluating the performance of OGM for
detection of cytogenetic abnormalities in myelodysplastic syndromes
(MDS) and acute myeloid leukemia (AML) samples. This work is the
second independent study, following a recent publication from
researchers at MD Anderson Cancer Center, showing that OGM enables
better molecular characterization of MDS. This paper extends that
research to AML and the findings indicate that OGM may have an even
greater impact on the characterization of AML compared to MDS,
which led the researchers to recommend integrating OGM into new
prognostic scoring methods for both myeloid malignancies.
In the study published in Blood Cancer Journal, researchers
analyzed samples from 68 adult MDS and AML patients using OGM to
evaluate OGM’s performance in the detection of cytogenetic
abnormalities that may impact diagnosis and stratification into
groups for treatment. In 33% of MDS samples and 54% of AML samples,
the study reported more clinically relevant variants were detected
using OGM than were found by traditional cytogenetic methods and
these variants were reported to be highly relevant to the
understanding of pathogenesis of these disorders.
Additional findings of the study:
- The R-IPSS score was changed for 6 cases, which could impact
prognosis or assist in patient stratification.
- In 8 cases, OGM found clinically significant events (mainly
complex cytogenetics).
- OGM also detected balanced structural variants (SVs)
identifying partner genes of driver genes not routinely identified
by other techniques.
“What is gratifying about this study is that it confirms the
conclusions that were reported by MD Anderson regarding MDS and it
extends that work to include AML. These are areas where innovation
can play a big role in improvements in patient management as well
as the development of new approaches in disease diagnosis and
treatment,” commented Erik Holmlin, PhD, president and chief
executive officer of Bionano Genomics.
The publication can be found here:
https://www.nature.com/articles/s41408-022-00718-1
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome
through OGM solutions, diagnostic services and software. The
Company offers OGM solutions for applications across basic,
translational and clinical research. Through its Lineagen business,
the Company also provides diagnostic testing for patients with
clinical presentations consistent with autism spectrum disorder and
other neurodevelopmental disabilities. Through its BioDiscovery
business, the Company also offers an industry-leading,
platform-agnostic software solution, which
integrates next-generation sequencing and microarray data
designed to provide analysis, visualization, interpretation and
reporting of copy number variants, single-nucleotide variants and
absence of heterozygosity across the genome in one consolidated
view. For more information, visit www.bionanogenomics.com,
www.lineagen.com or www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “could,” “believe” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the ability and utility of OGM to detect SVs in MDS or AML, the
utility and adoption of using OGM in determining prognostic scores
for MDS and AML, and the ability of OGM to detect clinically
relevant SVs and provide a more comprehensive analysis of the
genome for applications in genetic disease and cancer. Each of
these forward-looking statements involves risks and uncertainties.
Actual results or developments may differ materially from those
projected or implied in these forward-looking statements. Factors
that may cause such a difference include the risks and
uncertainties associated with: the impact of the COVID-19 pandemic
on our business and the global economy; general market conditions;
changes in the competitive landscape and the introduction of
competitive technologies or improvements to existing technologies;
failure of future study results to support those demonstrated in
the paper referenced in this press release; failure OGM to detect
clinically relevant SVs in MDS or AML; failure of the market to
adopt the use of OGM into new prognostic scoring methods for
myeloid malignancies; our ability to obtain sufficient financing to
fund our strategic plans and commercialization efforts; the ability
of medical and research institutions to obtain funding to support
adoption or continued use of our technologies; and the risks and
uncertainties associated with our business and financial condition
in general, including the risks and uncertainties described in our
filings with the Securities and Exchange Commission, including,
without limitation, our Annual Report on Form 10-K for the year
ended December 31, 2021 and in other filings subsequently made by
us with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2023 to Apr 2024